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Abstract. The insulin-like growth factor 1 receptor (IGF1R) 
pathway plays an important role in the pathogenesis of non-small 
cell lung cancer (NSCLC) and also provides a mechanism of 
resistance to targeted therapies. IGF1R is therefore an ideal ther-
apeutic target and several inhibitors have entered clinical trials. 
However, thus far the response to these inhibitors has been poor, 
highlighting the importance of predictive biomarkers to identify 
patient cohorts who will benefit from these targeted agents. It 
is well-documented that mutations and/or deletions in the 
epidermal growth factor receptor (EGFR) tyrosine kinase (TK) 
domain predict sensitivity of NSCLC patients to EGFR TK 
inhibitors. Single-nucleotide polymorphisms (SNPs) in the IGF 
pathway have been associated with disease, including breast and 
prostate cancer. The aim of the present study was to elucidate 
whether the IGF1R TK domain harbours SNPs, somatic muta-
tions or deletions in NSCLC patients and correlates the mutation 
status to patient clinicopathological data and prognosis. Initially 
100 NSCLC patients were screened for mutations/deletions in 
the IGF1R TK domain (exons 16-21) by sequencing analysis. 
Following the identification of SNP rs2229765, a further 
98 NSCLC patients and 866 healthy disease-free control 
patients were genotyped using an SNP assay. The synonymous 
SNP (rs2229765) was the only aberrant base change identified 
in the IGF1R TK domain of 100 NSCLC patients initially anal-
ysed. SNP rs2229765 was detected in exon 16 and was found to 
have no significant association between IGF1R expression and 
survival. The GA genotype was identified in 53.5 and 49.4% 
of NSCLC patients and control individuals, respectively. No 
significant difference was found in the genotype (P=0.5487) 
or allele (P=0.9082) frequencies between the case and control 
group. The present findings indicate that in contrast to the EGFR 
TK domain, the IGF1R TK domain is not frequently mutated 
in NSCLC patients. The synonymous SNP (rs2229765) had no 
significant association between IGF1R expression and survival 
in the cohort of NSCLC patients.
Introduction
The role of the insulin-like growth factor 1 receptor (IGF1R) 
in the pathogenesis of malignant epithelial tumours, including 
non-small cell lung cancer (NSCLC), has been well-charac-
terised (1-5). Activation of this receptor pathway promotes 
tumour growth by inhibition of apoptosis, transformation, 
metastasis and induction of angiogenesis through vascular 
endothelial growth factor (6-10).
IGF1R is frequently overexpressed in NSCLC patients, 
however, there is controversy over its significance as a prog-
nostic marker. Certain studies have shown no correlation 
between high IGF1R expression and patient survival (3,4); 
conversely, other studies have demonstrated that high IGF1R 
expression was associated with nodal metastasis, recurrence 
and a significantly poorer overall survival (OS) rate in NSCLC 
patients (11,12). A recent meta-analysis suggests IGF1R positive 
expression as an adverse factor for disease-free survival (DFS) 
in NSCLC patients and reports the correlation to smoking 
status and tumour size, but there was no significant association 
between IGF1R expression and OS on univariate or multivariate 
analysis (13). Ludovini et al (14) reported that high co‑expres-
sion of IGF1R and epidermal growth factor receptor (EGFR) is 
associated with a shorter DFS in resected NSCLC patients and 
a trend towards a poorer OS. We have previously shown that 
high co-expression of EGFR and IGF1R correlates with poor 
patient prognosis in resected NSCLC (15).
Following the success of other targeted therapies, such 
as the EGFR inhibitors, IGF1R also emerged as an attractive 
therapeutic target. Although the results from early clinical 
trials targeting IGF1R showed certain promise, larger random-
ized phase III trials have not shown a clear clinical benefit of 
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targeting this pathway in combination with chemotherapy (16). 
The results of these trials and others involving targeted agents 
have demonstrated the importance of identifying predictive 
biomarkers to select the appropriate patient population who 
will benefit from treatment.
Somatic mutations in the kinase domain of a receptor can 
cause the cell to become highly dependent on the constitutively 
active receptor signalling pathway. These aberrations can also 
cause conformational changes that can impact on the binding 
capabilities of a therapeutic agent targeting this region (17-22). 
As many as 2,412 single‑nucleotide polymorphisms (SNPs) 
have been identified in IGF1R and several have been associ-
ated with a cancer risk (22-26). A common polymorphism of 
the IGFIR gene (G1013A) has been shown to modify the risk 
of obesity for esophageal adenocarcinoma and, in combination 
with a polymorphism in IGF2R (G1619A), is an independent 
prognostic factor in advanced NSCLC (27-29). A previous study 
has shown that the IGF1 pathway polymorphisms are potential 
predictive/prognostic molecular markers for cetuximab effi-
cacy in wild-type KRAS colorectal cancer patients (30). These 
polymorphisms may activate crosstalk between the IGF1R and 
EGFR signalling pathways. A study by Deming et al (31) on 
genetic variation in patients with breast cancer found that SNP 
rs951715 within the IGF1R gene was associated with breast 
cancer survival in postmenopausal women. Another polymor-
phism, SNP rs2229765, appears to be a silent mutation with 
no correlation to survival rate in breast cancer patients and 
thus far has no association with any epidemiological traits. In 
a retrospective study of 304 NSCLC patients who underwent 
curative pulmonary resection,  1 silent mutation in exon 16 and 
3 intronic mutations were detected within the IGF1R gene but 
did not correlate to IGF1R protein expression (32).
Identifying functional polymorphisms in the IGF1R 
pathway could be used to select patients who may benefit from 
IGF1R-targeted agents. Thus far, there have been few reports of 
SNPs or somatic mutations in the IGF1R tyrosine kinase (TK) 
domain. Therefore, the aim of the present study was to screen 
NSCLC patients, who had undergone lung tumour resection 
surgery, for gene aberrations in the IGF1R TK domain.
Materials and methods
Subjects. This is a retrospective study in which a database 
of all the patients who underwent curative-intent surgical 
resection of a primary tumour at St. James's Hospital, 
Dublin (Republic of Ireland) between February 2001 and 
February 2005, was analysed. A cohort of 198 stage I-III 
NSCLC patients, staged according to the International System 
of Staging for Lung Cancer (33), was randomly selected 
from the database. Information on baseline demographics, 
clinicopathological characteristics and surgical approach 
was collected following a review of clinical notes and histo-
pathology reports. Outcome data, including peri-operative 
mortality and long-term survival, were updated prospectively. 
Patient characteristics are detailed in Table I. The study was 
approved by the St. James's Hospital Ethics Committee. 
Controls (n=866) were ascertained with written informed 
consent from the Trinity Biobank and represented blood 
donors from the Irish Blood Transfusion Service recruited in 
the Republic of Ireland. Individuals taking regular prescribed 
medication are excluded from blood donation in the Republic 
of Ireland and donors are not financially remunerated.
DNA extraction. DNA was extracted from 3x10-µm 
formalin-fixed paraffin-embedded sections from NSCLC 
patients and prepared using the QIAamp® DNA kit. DNA 
was extracted from control blood samples using the Gentra 
Autopure system (Qiagen, Hilden, Germany).
PCR amplification of exons 16‑20. The primer sequences used 
for the PCR reactions are outlined in Table II. The following 
PCR conditions were used: 1X GoTaq® Green Master 
mix (Promega Corp., Madison, WI, USA), 5 µM of forward 
and reverse primers and 100 ng of DNA made up to a volume 
of 50 µl with dH20. A pre‑PCR heat step of 94˚C for 5 min was 
carried out to activate the enzyme and the DNA was amplified 
for 35 cycles at 94˚C (1 min), 56˚C (1 min) and 72˚C (1 min), 
and at 72˚C (10 min) after the last cycle. A portion of the PCR 
product was electrophoresed on a 1.4% agarose gel to verify 
product integrity. PCR products were purified using the Qiagen 
QIAquick PCR purification kit. The DNA was measured using 
the NanoDrop 1000 spectrophotometer.
Sanger sequencing of PCR products. Sanger sequencing 
reactions were set up as follows: 2 µl BigDye® Terminator 
mix v3.1, 50 ng DNA, 5 µM forward or reverse primers and 
2 µl sequencing buffer, diluted to 20 µl with water. A posi-
tive control was also set up to ensure the efficiency of the 
sequencing reaction (1 µl pGem, 2 µl M13 primer, 2 µl BigDye® 
Terminator mix v3.1 and 2 µl sequencing buffer). The pGem 
and BigDye® Terminator mix v3.1 were sourced from Applied 
Biosystems (Warrington, UK). Sequencing was performed 
on a 3130xl genetic analyser (Applied Biosystems, Foster 
City, CA, USA) and sequencing files were analysed using the 
BioEdit v 7.0.8 (Ibis Biosciences, Carlsbad, CA, USA).
SNP genotyping assay. A TaqMan® SNP genotyping 
assay (Applied Biosystems) that detected the SNP at codon 
3179A>G (rs2229765) in exon 16 of the TK domain by 
quantitive PCR was also used to screen patients. TaqMan® 
SNP Genotyping Assay 5' nuclease technology uses two 
allele‑specific TaqMan® MGB probes and a PCR primer pair 
to detect the specific SNP target. The probes and primers 
uniquely align with the genome, enabling TaqMan® geno-
typing technology to provide unmatched specificity. Genotype 
data for rs2229765 was generated on the control samples using 
the Genome-Wide Human SNP Array 6.0 (Affymetrix, Inc., 
Santa Clara, CA, USA) (34).
Immunohistochemistry. IGF1R immunohistochemical analysis 
was performed on 4‑µm slides cut from 22 tissue microarrays 
and mounted on Superfrost Plus glass slides (Thermo Fisher 
Scientific, Inc., Waltham, MA, USA). The entire staining 
procedure was performed on an automated immunohisto-
chemistry device [BenchMark XT; Ventana Medical Systems, 
Inc. (VMS), Tucson, AZ, USA] following the manufacturer's 
instructions. In brief, slides were deparaffinized on the ther-
mopads using the Ez Prep reagent (950‑102; VMS). For 
epitope recovery, the standard CC1 buffer, a citric-acid-based 
antigen retrieval solution, was used (950‑102; VMS). All the 
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subsequent washing and blocking steps followed standard 
protocols. Slides were incubated with the prediluted primary 
antibody (monoclonal rabbit anti‑IGF1R, clone G11; VMS) 
for 16 min at 37˚C. Negative controls included identically 
processed slides in which the primary antibody was replaced 
by accordingly diluted non-immune rabbit IgG (Abcam, 
Cambridge, UK; 27478). Positive controls included identi-
cally treated paraffin slides of a H322M xenograft, an 
IGF1R-overexpressing NSCLC cell line. Detection of primary 
antibody binding was performed using the ultraView Universal 
DAB Detection kit (760‑091; VMS). After the diaminobenzi-
dine (DAB) reaction was developed, slides were counterstained 
with haematoxylin II (760‑500; VMS), dehydrated in a serial 
dilution of ethanol, transferred in xylene and mounted with 
Eukitt (O. Kindler GmbH, Freiburg im Breisgau, Germany).
Statistical analysis. The software package SPSS v16.0 (SPSS 
Inc., Chicago, IL, USA) was used to perform the statistical 
analysis. χ2 test, Cox regression analysis, Kaplan-Meier 
analysis and the log-rank test were used to illustrate the 
significance of various clinical characteristics. Assumption of 
the proportional hazard was tested for all covariates. P<0.05 
was considered to indicate a statistically significant difference.
Results
Initially, 100 NSCLC patients were screened for the presence of 
mutations, deletions or SNPs in exons 16-20 of the TK domain of 
IGF1R. The polymorphism (rs2229765) located on exon 16 of the 
IGF1R gene (GenBank accession NM_000875), consisting of a 
G to A transition at nucleotide 3174 but not leading to an amino 
acid change (Glu‑>Glu) at position 1043 (E1043E) (GenBank 
accession NP_000876), was identified (Table III). No other 
mutations, deletions or SNPs were found in the TK domain. A 
further 98 NSCLC patients were screened for the presence of the 
same SNP (rs2229765) and compared to the control disease-free 
individuals (n=866). The control patient DNA used came from 
Table I. Patient characteristics.
Characteristics Cases, n Controls, n
Total 198 866
Gender
  Male 125 296
  Female   73 570
Smoking history
  Former 130 ND
  Current   57 ND
  Never   11 ND
Histology
  SCC   94 ND
  ADC   84 ND
  Other   20 ND
Age, years
  <50   28 698
  >50 170 168
ND, not determined.
Table II. Primer sequences used for amplification of IGF1R 
RTK 1-6.
Exon Primer sequence (5'-3')
RTK1 F: GGCTTGTTTCTGTACCTGCT
 R: AGCCAAGAACATACTGGGAG
RTK2 F: ACAACACAGGCATCAGCAAG
 R: GACACAGCATTTCCTTGCAG
RTK3 F: CTCGAAAGAAATTGGCATGG
 R: TCTCCAGGGGCAGACTAATG
RTK4 F: CTGCTCCAGCGTGTGACTCT
 R: GAGCTAAAGCTGGCAACGGG
RTK5 F: CTGCTCGGGATGTAAGAAGT
 R: CTCCTAATCTCCTGTGACCC
RTK6 F: CGTACGAGGTAAACAGGAG
 R: AGCTTGTTCTCCTCGCTGTA
IGF1R, insulin‑like growth factor 1 receptor; RTK, receptor tyrosine 
kinase; F, forward; R, reverse.
Table III. Characteristics for the SNP rs2229765, evaluated in 
the present study.
Characteristics SNP
Gene name IGF1R
Alleles, major>minor G>A
SNP reference ID rs2229765
Position in gene Exon 16
Codon Glu1013Glu
Polymorphism data on SNP rs2229765 was retrieved from the NCBI 
SNP reference database. SNP, single-nucleotide polymorphism.
Table IV. Genotypic and allelic frequency of SNP rs2229765 in 
NSCLC and control patients.
 NSCLC patients Control patients 
Frequency (n=198), n (%) (n=866), n (%) P‑value
Genotype
  AA   35 (17.7) 175 (20.2) 0.5487
  GA 106 (53.5) 428 (49.4) 
  GG   57 (28.8) 263 (30.3)
Allele
  A 176 (44.4) 778 (44.9) 0.9082
  G 220 (55.5) 954 (55.0)
SNP, single‑nucleotide polymorphisms; NSCLC, non‑small cell lung 
cancer.
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the Trinity Biobank in the Institute of Molecular Medicine, 
Trinity College Dublin. These results where subsequently corre-
lated to patient survival/pathological data. Example sequence 
traces from a homozygous G/G patient and a heterozygous 
A/G patient are shown in Fig. 1A and B, respectively.
The heterozygous GA genotype was found in 
53.5 and 49.4% of NSCLC patients and controls, respec-
tively (Table IV). The dominant GG genotype was identified 
in 28.8 and 30.3% of NSCLC patients and control individuals, 
respectively, while the recessive AA genotype was found in 
17.7 and 20.2% of NSCLC patients and control individuals, 
respectively. No significant difference was found in the geno-
type (P=0.5487) frequency between cases and controls. The 
A allele was identified in 44.4 and 44.9% of NSCLC patients 
and control individuals, respectively, while the G allele was 
identified in 55.5 and 55% of NSCLC patients and control indi-
viduals, respectively. No significant difference was identified 
in the allelic (P=0.9082) frequency.
From the overall patient and control cohorts, patients 
>70 years were excluded as there were no matched controls avail-
able for this age group. Age and gender matching ensures that 
any difference between cases and controls is disease-related. The 
genotypic and allelic frequencies were subsequently examined 
in 95 NSCLC patients and 95 age- and gender-matched control 
individuals. When patients were age- and gender-matched the 
GA genotype was identified in 56.8 and 48.4% of NSCLC and 
control patients, respectively (Table V). The dominant GG 
genotype was identified in 22.1 and 29.4% of NSCLC patients 
and control individuals, respectively, while the recessive AA 
genotype was identified in 21.0 and 22.1% of NSCLC patients 
and control individuals, respectively. No significant difference 
was identified in the genotype (P=0.4351) frequency. The 
A allele was identified in 49.4 and 46.3% of NSCLC patients 
and control individuals, respectively, while the G allele was 
identified in 50.5 and 53.6% of NSCLC patients and control 
individuals, respectively. No significant difference was found in 
the allelic (P=0.2636) frequency.
IGF1R expression and survival data were available for 
100 NSCLC patients. IGF1R expression was compared to 
the results of the genotype distribution in NSCLC patients 
using Kaplan-Meier analysis. Results showed no signifi-
cant difference in genotype distribution (Fig. 2) or IGF1R 
Figure 1. Forward sequence traces from a non-small cell lung cancer (NSCLC) patient with (A) no single-nucleotide polymorphism (SNP) (homozygous G/G) 
and (B) a heterozygous SNP (SNP 3179A>G) in exon 16.
Figure 2. Kaplan-Meier plot of genotype distribution of SNP rs2229765 in 
non‑small cell lung cancer (NSCLC) patients (log rank test P=0.3564).
  A
  B
Figure 3. Kaplan-Meier plot correlating insulin-like growth factor 1 
receptor (IGF1R) expression to genotype distribution of SNP rs2229765 
in non-small cell lung cancer (NSCLC) patients. (A) Heterozygous A/G, 
(B) homozygous dominant GG and homozygous recessive AA. Log rank test 
(A) P=0.3005 and (B) P=0.1164.
  A
  B
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expression (Fig. 3A and B) in NSCLC patients. Analysis 
of genotype distribution in NSCLC patients showed 
that the P‑value was 0.3564 while the P‑value for trend 
was 0.1514 (Fig. 2). Analysis correlating IGF1R expression 
to genotype distribution in NSCLC patients showed that the 
P-value was 0.3005 while the P-value for trend was 0.7099 in 
patients with heterozygous genotype (Fig. 3A), and that the 
P‑value was 0.1164 while the P‑value for trend was 0.0277 for 
patients with homozygous dominant and homozygous reces-
sive genotype (Fig. 3B).
Discussion
A number of previous studies have identified factors that may 
influence sensitivity to IGF1R inhibitors. Kim et al (35) evalu-
ated the anti‑proliferation effect of figitumumab in gastric 
and hepatocellular cancer cell lines and showed that the level 
of N-linked glycosylated IGF1R/IR heterodimeric receptor 
is highly associated with sensitivity to anti-IGF1R antibody 
in cancer cells. Another study demonstrated that IGF1R TK 
inhibitors (TKIs) exhibited significant antitumor activity in 
NSCLC cells with wild-type EGFR and KRAS compared to 
those with mutations in these genes (36).
Although SNPs have been reported in IGF1R, there is 
limited knowledge regarding the frequency of gene aberra-
tions in the TK domain of this gene. Patients who harbour 
point mutations and deletions within exons 18-21 of the EGFR 
TK domain are known to have increased sensitivity to EGFR 
TKIs. Therefore, the mutation status of the IGF1R TK domain 
may also influence the binding of IGF1R TKIs to this receptor 
and therefore influence patient response to targeted therapy.
The present study investigated the frequency of gene 
aberrations in the IGF1R TK domain in NSCLC patients and 
whether such changes may influence IGF1R expression or 
survival rate. Initially, 100 NSCLC patients were screened for 
the presence of mutations and or deletions in exons 16-21 of 
the IGF1R TK domain. No non-synonymous SNPs or dele-
tions were detected in any of the 100 patients screened. A 
synonymous SNP (rs2229765) was identified in the coding 
region of exon 16. In order to strengthen the power of the study, 
a further 98 NSCLC patients were screened for the presence 
of the SNP (rs2229765) and the frequency was compared to 
control disease‑free individuals (n=866). No significance was 
found in the genotype (P=0.5487) or the allelic (P=0.9082) 
frequency (Table IV).
When patients were age- and gender-matched, no 
significance was identified in the genotype (P=0.4351) or the 
allelic (P=0.2636) frequency (Table V). The Kaplan-Meier 
survival analysis showed no significant survival advantage 
between the different genotypes in NSCLC patients (Fig. 2). 
There was also no significant difference when IGF1R expres-
sion was correlated to heterozygous genotype distribution in 
NSCLC patients. A significant difference for trend (P<0.05) 
was observed when IGF1R expression was correlated to 
combine the homozygous dominant and homozygous reces-
sive genotype distribution in NSCLC patients (Fig. 3A and B).
The role of the SNP, rs2229765, has been examined in 
several diseases such as stroke breast cancer and type II 
diabetes. It is a synonymous mutation that encodes a change 
in the DNA sequence without altering the resultant protein 
sequence. These silent SNPs are presumed to be not significant 
but they may represent genetic markers for functional molec-
ular alterations, as recent studies have revealed that through 
various mechanisms these synonymous SNPs may affect 
gene function and phenotype. Silent SNPs have been linked 
to >40 diseases that are a result of a genetic abnormality (37).
The possible role of this SNP has been investigated in 
numerous studies. According to FASTSNP, it is predicted 
that SNP rs2229765 may affect splicing regulation. It has 
been shown to affect the susceptibility to ischemic stroke in 
the Chinese population (38) and is associated with higher 
plasma concentrations of circulating IGF1R. In a study by 
Bonafè et al (39), polymorphic variants of the IGF1 response 
pathway genes, including IGF1R (G/A, codon 1013), phos-
phoinositol 3-kinase (T/C, 359 bp; A/G, 303 bp), insulin receptor 
substrate-1 (G/A, codon 972) and FOXO1A (T/C, 97,347 bp), 
were examined to observe whether they are involved in systemic 
IGF1 regulation and human longevity. It was found that subjects 
carrying at least an A allele at IGF1R have low free plasma 
IGF1 levels and live longer. A study performed in breast cancer 
identified that SNP rs2229765 had no association with breast 
cancer survival and that it appears to be a silent mutation (31). 
Therefore, thus far it has not been associated with any epide-
miological traits. In another study, single SNP analysis revealed 
a significant association of SNP rs2229765 with percent and 
absolute mammographic density; increased numbers of the 
G allele increased the least squares means of mammographic 
density (40). The possible role of this polymorphism has also 
been examined in type II diabetes, which revealed no association 
with reduced birth weight, insulin sensitivity index or type II 
diabetes in a Danish population (41). These results also suggest 
that the rs2229765 polymorphism leads to a silent mutation.
A previous study investigated whether germline polymor-
phisms of the IGF1-pathway are associated with the response 
to cetuximab in wild-type KRAS drug-refractory metastatic 
colorectal cancer patients (mCRC) (28). Tissue samples from 
130 drug-refractory mCRC patients enrolled in a phase II clin-
ical trial of cetuximab monotherapy (IMC‑0144) were used for 
the study. Analyses revealed that 5 IGF-pathway SNPs were 
Table V. Genotypic and allelic frequency of SNP rs2229765 in 
the IGF1R TK domain of NSCLC and control patients (age- 
and gender-matched).
 NSCLC patients Control patients 
Frequency (n=95), n (%) (n=95), n (%) P‑value
Genotype
  AA 20 (21.0) 21 (22.1) 0.4351
  GA 54 (56.8) 46 (48.4) 
  GG 21 (22.1) 28 (29.4)
Allele
  A 94 (49.4)   88 (46.3) 0.2636
  G 96 (50.5) 102 (53.6)
SNP, single‑nucleotide polymorphisms; IGF1R, insulin-like growth 
factor 1 receptor; TK, tyrosine kinase; NSCLC, non‑small cell lung 
cancer.
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significantly associated with progression‑free survival and/or 
OS. Patients harbouring the IGF1 rs2946834 A/A genotype 
had a 50% overall response rate, while patients with the A/G 
genotype had 0%. This indicates that IGF1‑pathway polymor-
phisms may predict cetuximab efficacy in wild‑type KRAS 
mCRC patients.
Identifying functional polymorphisms in IGF1R and its 
pathway could be used to select patients that would benefit 
from IGF1R-targeted therapy resulting in more accurate treat-
ment for individuals with improved effectiveness and reduced 
toxicities. In the present cohort of 100 NSCLC patients, no 
non-synonymous SNPs were detected in the IGF1R TK 
domain. There was no significant association between SNP 
rs2229765 and IGF1R expression or patient survival. This data 
indicates that the IGF1R TK domain does not appear to be 
as susceptible to mutations as EGFR. Therefore, as opposed 
to EGFR, it will not be necessary to screen for mutations in 
IGF1R to predict response to targeted therapy.
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